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Case Report
A Case of Rapidly Progressive Primary Sclerosing Cholangitis 
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Primary sclerosing cholangitis (PSC) is a slowly progressive cholestatic liver disease. In cases of PSC, liver transplantation 
is the only effective treatment that can delay the disease’s natural course. We report a case of rapidly progressive PSC 
requiring liver transplantation. A 52-year-old woman visited our hospital with abdominal pain. There was no evidence of 
PSC, as there was no elevation in cholestatic liver enzymes at her first visit. Although her total bilirubin was in a normal 
range at the initial visit, liver dysfunction progressed rapidly. Despite endoscopic procedures and ursodeoxycholic acid intake, 
total bilirubin levels rose to 18.9 mg/dL, and liver transplantation was performed 17 months after her first visit. PSC was 
pathologically confirmed after liver transplantation.
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Introduction
Primary sclerosing cholangitis (PSC) is a chronic 
cholestatic bile duct disease. According to a recent 
meta-analysis, its incidence was 0.77 per 100,000 per-
son-years(1). It is a rare disease and seems to occur at 
lower frequencies in Asia and Southern Europe than in 
America and Northern Europe(2).
PSC is often fatal as there are no effective treatments 
which can halt its progression with the exception of liv-
er transplant. In the case described here, there was no 
evidence of PSC except the elevated cholestatic liver 
enzymes at the initial visit of our hospital. However, 17 
months later, the patient’s liver dysfucntion had rapidly 
progressed, and a liver transplantation was performed.
Case Report
In September 2010, a 52-year-old woman visited our 
hospital presenting with abdominal pain which had 
been present for 1 month. She was taking antihyper-
tensive medication. Her sclera was not icteric, and 
there was no abdominal tenderness. A liver function 
test revealed the following: aspartate aminotransferase 
(AST) 110 IU/L, alanine aminotransferase (ALT) 119 
IU/L, total bilirubin 0.3 mg/dL, alkaline phosphatase 
(ALP) 400 IU/L, and γ-glutamyl transpeptidase (γ-GT) 
592 IU/L. Her hepatitis B surface antigen, antibody to 
hepatitis C virus, antihepatitis A virus immunoglobulin 
M were all negative. Tumor markers were carcinoem-
bryonic antigen 1.18 ng/mL and CA 19-9 24.3 U/mL. 
Esophagogastroduodenoscopy, colonoscopy, and abdo-
men computed tomography showed no abnormal 
findings. Cholestatic liver diseases such as PSC, pri-
mary biliary cirrhosis, or nonalcoholic fatty liver dis-
ease were suspected due to the elevated cholestatic 
liver enzyme levels. For further evaluation, autoimmune 
markers were checked. Her autoimmune markers: per-
inuclear antineutrophil cytoplasmic antibody, cytoplas-
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Fig. 1. (A) Eight months after the initial diagnosis of primary sclerosing cholangitis (PSC), the patient’s liver biopsy showed a mild
degree of lobular and portal activity, and portal fibrosis suggestive of chronic hepatitis (HE stain, ×400). (B) After liver transplantation,
which was done 17 months after the initial diagnosis, surgical pathology showed periductal lamellar fibrosis, called “onion-skin,”
a typical finding of PSC (HE stain, ×400).
mic antineutrophil cytoplasmic antibody, antinuclear 
antibody, antimitochondrial antibody, and antismooth 
muscle antibody were all negative. Immunoglobulin G, 
A, M quantification were 1,460, 192, and 261 mg/dL, 
respectively, subclass immunoglobulin G4 level was 
139.0 mg/dL. Although the diagnosis was unclear, ur-
sodeoxycholic acid (UDCA) intake was started at 10 
mg/kg/day, and serum ALP and aminotransferase lev-
els decreased. However, after 8 months (May 2011), 
the patient’s liver enzyme levels rose to: AST 65 IU/L, 
ALT 174 IU/L, total bilirubin 1.4 mg/dL, ALP 518 IU/L, 
and γ-GT 686 IU/L. We performed a liver biopsy and 
the pathology showed a mild degree of lobular and 
portal activity, and portal fibrosis suggestive of chronic 
hepatitis (Fig. 1A). The dose of UDCA was increased 
to 15 mg/kg/day. After 12 months (September 2011), 
the patient’s total bilirubin rose to 4.0 mg/dL. In or-
der to evaluate the cause of the obstructive jaundice, 
magnetic resonance cholangiopancreatography (MRCP) 
(Fig. 2A), and endoscopic retrograde cholangiopan-
creatography (ERCP) (Fig. 2B) were performed. These 
findings revealed multiple stones, strictures, and dilata-
tions of intrahepatic ducts, suggestive of PSC. Endos-
copic shpincterotomy was done and an endoscopic 
nasobiliary drainage tube was inserted by ERCP. After 
15 months (December 2011), the patient’s total bilir-
ubin and direct bilirubin rose to 13.9 and 11.1 mg/dL, 
respectively, and so MRCP was performed again. The 
mucosal irregularity had not changed from what was 
seen in the previous MRCP. To relieve the jaundice, 
stones were removed from the common bile duct and 
intrahepatic ducts by ERCP and percutaneous trans-
hepatic choledochoscopy (PTCS), respectively. A biop-
sy was performed using PTCS on an intraductal mu-
cosal lesion showing nodularity in the hilum, and the 
result showed fibrous exudates with chronic in-
flammatory cell infiltration. Despite extracting the stones, 
total bilirubin rose again to 18.9 mg/dL (Fig. 3), and 
direct bilirubin rose to 15.4 mg/dL. Although there 
were no complications such as ascites, hepatic ence-
phalopathy, bleeding, and hepatorenal syndrome, there 
was no treatment of choice to halt progression of liver 
dysfunction except liver transplantation. The patient’s 
MELD score was 26, and Child-Pugh score was 9. A 
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Fig. 2. Twelve months after the 
initial diagnosis of primary scleros-
ing cholangitis (PSC), (A) magnetic 
resonance cholangiopancreatogra-
phy and (B) endoscopic retrograde
cholangiopancreatography findings 
showed multiple dilatations and 
strictures of intrahepatic ducts, su-
ggestive of PSC. 
Fig. 3. The trend of total bilirubin,
alkalaine phosphatase, and alanine
aminotransferase (ALT) was descri-
bed. Abbreviations: PTCS, percuta-
neous transhepatic choledochoscopy;
ERCP, endoscopic retrograde chol-
angiopancreatography; LT, liver tra-
nsplantation; ALP, alkaline phos-
phatase; TB, total bilirubin.
Fig. 4. Gross finding of the explanted liver. The liver was mac-
ronodular, and diffusely bile stained.
liver transplant from living donor with duct to duct 
anastomosis was performed at 17 months (February 
2012) after the initial visit of our hospital. The ex-
planted liver weighed 1,600 g and measured 24 (right 
to left)×15 (superior to inferior)×12 cm (anterior to 
posterior) (Fig. 4). The surgical pathology of explanted 
liver reported a segmental bile duct showing concen-
tric fibrosis suggestive of PSC (Fig. 1B). The patient’s 
human leukocyte antigen (HLA) serotyping was A1, 
A24, B51, B52, DR1, and DR15. The elevated bilirubin 
levels rapidly decreased, and were in the normal 
range by 21 days after surgery. The patient is on ta-
crolimus hydrate since liver transplantation. General 
condition of the patients was markedly improved with-
out recurrence of cholangitis. However, at 5 months 
after liver transplantation, the anastomosis site stricture 
was found in abdomen computed tomography, and 
percutaneous biliary tract drainage (PTBD) was inserted. 
At 11 months after liver transplantation, PTBD was re-
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moved, and endoscopic retrograde biliary drainage 
was inserted.
Discussion
PSC is a chronic cholestatic liver disease leading to 
liver cirrhosis and liver failure. It is a slowly progressive 
disease(3) and the median survival from diagnosis to 
liver transplantation or death is 9.6∼12 years(4,5). 
Previous studies have reported that HLA-DR4 and 
DRw52a are markers for rapid disease progression in 
PSC(6,7), but this is still controversial(8). In our pa-
tient, HLD-DR4 and DRw52a were not observed, but 
her liver dysfunction progressed rapidly, and 17 
months after her initial diagnosis a liver transplant was 
necessary.
PSC can be diagnosed when cholangiography shows 
multifocal strictures and segmental dilatations of bile 
ducts with elevated cholestatic liver enzyme levels(9). 
Inflammatory bowel disease is found in 60∼80% of 
PSC patients and can be a clue for PSC diagnosis(9). 
In this case, the patient first visited our hospital com-
plaining of abdominal pain without any evidence of 
inflammatory bowel disease, and laboratory results re-
vealed elevated levels of alkalaine phosphatase and 
aminotransferase without any elevation of total bilirubin.
Although liver biopsies can be done to determine 
the stage of PSC and to exclude coexisting liver dis-
eases, this is not essential for diagnosis. In 98.7% of 
PSC patients, liver biopsies showed no atypical find-
ings(10). In this case, a liver biopsy was done but on-
ly indicated chronic hepatitis. The nodular lesion at 
the hilum portion of an intrahepatic duct was also bi-
opsied by PTCS to exclude cholangiocarcinoma, which 
is often concomitant with PSC, and the pathology 
showed chronic inflammation without malignancy. Nine 
months after the first liver biopsy, a surgical specimen 
obtained during the liver transplantation showed peri-
ductal lamellar fibrosis, a typical pathologic finding in 
PSC.
Until now, there has been no definitive treatment for 
PSC except liver transplantation. Some retrospective 
studies reported survival benefits in PSC when endo-
scopic treatments such as sphincterotomy, balloon di-
latation, stent insertion, or stone extraction were per-
formed to relieve dominant strictures(11,12). A domi-
nant stricture is a stenosis with a diameter of ≤1.0 
mm in a hepatic duct or ≤1.5 mm in a common 
duct(13). However, in PSC, the effectiveness of these 
endoscopic procedures is still unclear because there 
have been no randomized controlled studies to report 
on the benefits(9). Some studies have reported that 
UDCA improved liver function, but they failed to dem-
onstrate if it halted PSC progression(14-16). Furthermore, 
recent studies revealed that high-dose UDCA (28∼30 
mg/kg/day) did not improve patient survival and was 
associated with severe adverse effects(17,18). Due to 
this lack of clarity of the effectiveness of UDCA, recent 
guidelines recommend against the use of UDCA(9).
In summary, we described a patient with rapidly 
progressive PSC, which was pathologically confirmed 
after liver transplantation. PSC is a very rare disease in 
Korea and is typically a chronic disease. The patient 
visited our hospital because of abdominal pain without 
jaundice, but after 17 months, liver transplantation was 
performed due to decreased liver function. Although 
an endoscopic treatment was performed and stand-
ard-dose UDCA was administered, disease progression 
was not slowed. After liver transplantation, the pa-
tient’s liver function recovered fully.
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